Nexvet (NVET) Files $60M IPO

Nexvet (NASDAQ: NVET) filed with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $60 million. The company has applied to list its shares on NASDAQ Capital Market under the symbol "NVET"

BofA Merrill Lynch and Cowen & Company are the book-running managers. Piper Jaffray and JMP Securities are co-managers.

Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent some of the top-selling therapies on the market today. The company's proprietary platform, which we refer to as "PETization," is an algorithmic approach that enables us to rapidly create monoclonal antibodies that are designed to be recognized as "self" or "native" by an animal’s immune system, a property they refer to as "100% species-specificity." PETization is also designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals, thereby reducing clinical risk and development cost.

Link to S-1

You May Also Be Interested In

• Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
• Dynatrace plans to pursue FedRAMP High government security status
• Forgent Power Solutions prices public offering at $49 per share